Daiichi Sankyo Signs Agreement with Translational Sciences, Inc. to Develop and Commercialize the First-In-Class Thrombus Dissolving Agent, TS23

TOKYO, Japan (September 15, 2015) – Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) today announced that it has signed an exclusive licensing agreement with Translational Sciences, Inc. to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing Phase I clinical trials.

Based on this agreement, Daiichi Sankyo will pay Translational Sciences unspecified fees, milestones and royalties for exclusive rights to globally develop and commercialize TS23.

This agreement with Translational Sciences, Inc. for Daiichi Sankyo to develop and commercialize this unique thrombus dissolving agent, TS23, is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis.

Dr. Guy Reed, CSO/CEO of Translational Sciences said: “Daiichi Sankyo recognized the great potential of this novel therapy. We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy.”

About Translational Sciences
Translational Sciences, Inc. (Memphis, TN, USA) is a clinical stage, biopharmaceutical company that develops first-in-class therapeutics for the safe and effective treatment of acute cardiovascular diseases and ischemic stroke. Development of TS23 was supported by the National Institutes of Health, specifically the National Heart, Lung, And Blood Institute (Award R44HL092750) and the National Institute Of Neurological Disorders And Stroke (Award U44NS073147).*

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichisankyo.com.

*This press release does not necessarily represent the official views of the National Institutes of Health.